Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.
Molecular profiling will be performed on archival tumor tissue or freshly collected tumor tissue from re-biopsy. Blood, pleural fluid, FNA, and/or saliva may be collected to study the genetic makeup and also to compare the tumor molecular profile. Personalized therapy will be given based on molecular profile.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| tumor tissue for molecular profiling |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The molecular and clinical epidemiology for cancer patients being considered for novel therapeutics | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| The proportion of patients who have actionable alterations and enrol into clinical trials | 5 years | |
| The correlation of molecular profiles with clinical outcomes | 5 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Any advanced cancer patient who would benefit from molecular profiling and is a potential clinical trial candidate as identified by treating physician.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Daniel SW Tan | Contact | +65 6436 8000 | daniel.tan.s.w@singhealth.com.sg |
| Name | Affiliation | Role |
|---|---|---|
| Daniel SW Tan | National Cancer Centre, Singapore | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Cancer Centre, Singapore | Recruiting | Singapore | Singapore |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28874669 | Derived | Chia S, Low JL, Zhang X, Kwang XL, Chong FT, Sharma A, Bertrand D, Toh SY, Leong HS, Thangavelu MT, Hwang JSG, Lim KH, Skanthakumar T, Tan HK, Su Y, Hui Choo S, Hentze H, Tan IBH, Lezhava A, Tan P, Tan DSW, Periyasamy G, Koh JLY, Gopalakrishna Iyer N, DasGupta R. Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nat Commun. 2017 Sep 5;8(1):435. doi: 10.1038/s41467-017-00451-5. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Remaining tumor and/or blood and/or saliva and/or pleural fluid and/or FNA